Primary Graft Failure and Ca2+ Sensitizers After Heart Transplantation

Transplantation Proceedings

Volumn 40, Issue 4, 2008, Pages 951-952

  Beiras Fernandez, A ^a   Weis, F C ^a   Kur, F ^a   Kaczmarek, I ^a   Schmoeckel, M ^a   Weis, M ^a   Reichart, B ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CALCIUM SENSITIZER; LEVOSIMENDAN; MILRINONE; NORADRENALIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CARDIOPULMONARY HEMODYNAMICS; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG MEGADOSE; EVALUATION; FEMALE; GRAFT FAILURE; HEART EJECTION FRACTION; HEART FUNCTION; HEART TRANSPLANTATION; HEART VENTRICLE PERFORMANCE; HUMAN; MALE; MEAN ARTERIAL PRESSURE; POSTOPERATIVE CARE; PRIORITY JOURNAL; SURGICAL PATIENT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTROCARDIOGRAPHY; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HEART TRANSPLANTATION; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; PYRIDAZINES; STROKE VOLUME; TREATMENT FAILURE;

EID: 44849088113     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.106     Document Type: Article

References (10)

1. Mitropoulos F.A., Odim J., Marelli D., et al. Outcome of hearts with cold ischemic time greater than 300 minutes. A case-matched study. Eur J Cardiothorac Surg 28 (2005) 143
2. O'Connor C.M., Gattis W.A., Uretsky B.F., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 (1999) 78
3. Zimpfer D., Heinisch B., Czerny M., et al. Late vascular complications after extracorporeal membrane oxygenation support. Ann Thorac Surg 81 (2006) 892
4. Brixius K., Hoyer H.K., and Schwinger R.H. Ca (2+)-sensitisers-a promising option to treat heart failure?. Cardiovasc Drugs Ther 19 (2005) 423
5. Beiras-Fernandez A., Weis F.C., Fuchs H., et al. Levosimendan treatment after primary organ failure in heart transplantation: a direct way to recovery?. Transplantation 82 (2006) 1101
6. Jahania M.S., Mullett T.W., Sanchez J.A., et al. Acute allograft failure in thoracic organ transplantation. J Card Surg 15 (2000) 122
7. Szabo G., Sebening C., Hackert T., et al. Influence of brain death and cardiac preservation on systolic and diastolic function and coronary circulation in the cross-circulated canine heart. World J Surg 23 (1999) 36
8. Tisdale J.E., Patel R., Webb C.R., et al. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 38 (1995) 167
9. Lietz K., and Miller L.W. Will left-ventricular assist device therapy replace heart transplantation in the foreseeable future?. Curr Opin Cardiol 20 (2005) 132
10. Toller W.G., and Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 104 (2006) 556